Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL019 in Pediatric Relapsed/Refractory B-cell ALL
NCT02228096Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- May 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02228096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228096.